Published in Eur J Haematol on February 21, 2014
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. J Adolesc Young Adult Oncol (2015) 0.89
Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination. Cancer Chemother Pharmacol (2015) 0.76
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood (2010) 2.33
Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood (2007) 2.25
Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum (2011) 2.06
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant (2011) 1.90
Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood (2004) 1.77
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation. Haematologica (2006) 1.68
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol (2010) 1.57
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood (2002) 1.55
Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant (2011) 1.54
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. Mol Oncol (2010) 1.45
Does granulocyte colony-stimulating factor improve long-term outcome in adult acute lymphoblastic leukemia? Leuk Lymphoma (2009) 1.41
[Future care requires future ways of working]. Lakartidningen (2009) 1.39
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol (2005) 1.31
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: a retrospective population-based analysis from a single center. Leuk Lymphoma (2011) 1.27
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. Haematologica (2011) 1.25
Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood (2005) 1.22
Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant (2009) 1.15
Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol (2010) 1.09
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res (2007) 1.06
High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. Haematologica (2010) 1.03
Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum (2006) 0.99
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer (2010) 0.99
Gaucher disease with foamy transformed macrophages and erythrophagocytic activity. J Inherit Metab Dis (2010) 0.98
Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Biol Blood Marrow Transplant (2003) 0.98
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Res Treat (2008) 0.97
Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med Oncol (2008) 0.95
Treatment of multiple myeloma in patients with Gaucher disease. Am J Hematol (2009) 0.94
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol (2013) 0.92
Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma. Leuk Res (2010) 0.92
Portal vein thrombosis is a common complication following splenectomy in patients with malignant haematological diseases. Eur J Haematol (2006) 0.91
A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant (2013) 0.90
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol (2003) 0.89
TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype. Leuk Res (2008) 0.88
Population-based analyses in adult acute lymphoblastic leukemia. Blood (2010) 0.88
Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol (2002) 0.88
Cigarette smoking and risk of Hodgkin lymphoma: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 0.88
Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol (2007) 0.88
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation. Med Oncol (2011) 0.87
Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci (2012) 0.86
Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers. Clin Cancer Res (2008) 0.86
MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia. Eur J Haematol (2010) 0.86
High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia. Br J Haematol (2002) 0.85
High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. Haematologica (2012) 0.85
Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm (2006) 0.85
Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer (2013) 0.84
Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia. Leuk Lymphoma (2011) 0.83
IL-9 expression contributes to the cellular composition in Hodgkin lymphoma. Eur J Haematol (2006) 0.83
U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner. Eur J Haematol (2008) 0.82
Parental age, family size, and offspring's risk of childhood and adult acute leukemia. Cancer Epidemiol Biomarkers Prev (2012) 0.82
The pattern of deoxycytidine- and deoxyguanosine kinase activity in relation to messenger RNA expression in blood cells from untreated patients with B-cell chronic lymphocytic leukemia. Biochem Pharmacol (2006) 0.82
The GNAS1 T393C polymorphism and lack of clinical prognostic value in chronic lymphocytic leukemia. Leuk Res (2007) 0.82
Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB. Eur J Haematol (2003) 0.82
Low plasma levels of the protein pro-LL-37 as an early indication of severe disease in patients with chronic neutropenia. Br J Haematol (2007) 0.81
Genomic imbalances during transformation from follicular lymphoma to diffuse large B-cell lymphoma. Mod Pathol (2006) 0.81
BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution. Br J Haematol (2009) 0.81
Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use? Med Oncol (2007) 0.81
Analysis of a clonally related mantle cell and Hodgkin lymphoma indicates Epstein-Barr virus infection of a Hodgkin/Reed-Sternberg cell precursor in a germinal center. Am J Surg Pathol (2003) 0.81
Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma. Med Oncol (2010) 0.80
Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol (2012) 0.80
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr (2012) 0.80
Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica (2005) 0.80
High expression of microRNA-200c predicts poor clinical outcome in diffuse large B-cell lymphoma. Oncol Rep (2012) 0.79
An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients. Haematologica (2008) 0.78
Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study. Acta Oncol (2014) 0.78
[Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia]. Pol Arch Med Wewn (2002) 0.78
Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival? Leuk Lymphoma (2012) 0.78
Impact of imiglucerase supply shortage on clinical and laboratory parameters in Norrbottnian patients with Gaucher disease type 3. Arch Immunol Ther Exp (Warsz) (2014) 0.78
Low expression of microRNA-129-5p predicts poor clinical outcome in diffuse large B cell lymphoma (DLBCL). Int J Hematol (2013) 0.78